secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2026-08-05T20:18:02+00:00
Accession:  0001703057-26-000044
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera Q2 net loss widens to $55.4M; revenue drops to $4.1M; new Jazz, Vertex deals
--------------------------------------------------------------------------------

- Net loss of $55.4M ($0.18/sh) vs $34.7M ($0.12/sh) in Q2 2025; revenue $4.1M vs $17.1M.
- Ended quarter with >$565M cash and marketable securities; total liquidity >$675M.
- Announced collaborations with Jazz ($84M upfront) and Vertex ($28M upfront) for T-cell engagers.
- ABCL635 Phase 2 top-line data expected in August 2026; ABCL575 Phase 1 data expected Q4 2026.
- Partner programs progressing: 35 (down from 44 at Dec 2025); 12 molecules in clinic.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000044/0001703057-26-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000044/abcl-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001703057-26-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer